ASND vs GRFS
Ascendis Pharma A/S and Grifols SA, side by side — 10 fiscal years reported in EUR, drawn from SEC filings.
Most recent reported year
| Metric | ASND | GRFS |
|---|---|---|
| Revenue | €720.1M | €7.2B |
| Net income | €-228.0M | €156.9M |
| Gross margin | 86.8% | 38.7% |
| Net margin | −31.7% | 3.0% |
| Return on equity | · | 2.8% |
| Diluted EPS | −€3.76 | €0.23 |
| Dividend / share | · | · |
| Payout ratio | · | 0.6% |
| Free cash flow | · | €669.6M |
| Equity | · | €5.9B |
| Net debt / equity | · | · |
| Current ratio | 1.04× | 2.66× |
| Revenue CAGR 5y | 153.0% | 7.2% |
| Profit CAGR 5y | · | −24.2% |
GRFS bills 10.0× the revenue of ASND, and ASND closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | ASND | GRFS |
|---|---|---|
| FY2024 | €363.6M | €7.2B |
| FY2023 | €266.7M | €6.6B |
| FY2022 | €51.2M | €6.1B |
| FY2021 | €7.8M | €4.9B |
| FY2020 | €7.0M | €5.3B |
| FY2019 | €13.4M | €5.1B |
| FY2018 | €10.6M | €4.5B |
| FY2017 | €1.5M | €4.3B |
| FY2016 | €4.6M | €4.0B |
| FY2015 | €8.1M | €3.9B |
Bottom line
| Fiscal year | ASND | GRFS |
|---|---|---|
| FY2024 | €-378.1M | €156.9M |
| FY2023 | €-481.4M | €42.3M |
| FY2022 | €-583.2M | €185.0M |
| FY2021 | €-383.6M | €188.7M |
| FY2020 | €-419.0M | €618.5M |
| FY2019 | €-218.0M | €625.1M |
| FY2018 | €-130.1M | €596.6M |
| FY2017 | €-123.9M | €662.7M |
| FY2016 | €-68.5M | €545.5M |
| FY2015 | €-32.9M | €532.1M |
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2024 | −€6,848,741,000 | GRFS |
| FY2023 | −€6,325,259,000 | GRFS |
| FY2022 | −€6,012,793,000 | GRFS |
| FY2021 | −€4,925,340,000 | GRFS |
| FY2020 | −€5,333,085,000 | GRFS |
| FY2019 | −€5,085,316,000 | GRFS |
| FY2018 | −€4,476,143,000 | GRFS |
| FY2017 | −€4,316,543,000 | GRFS |
| FY2016 | −€4,045,224,000 | GRFS |
| FY2015 | −€3,926,445,000 | GRFS |
GRFS has reported the higher revenue in every one of these 10 fiscal years. The gap has widened since the earliest year compared.
10 of 11 comparable fiscal years — a year missing data on either side is not counted.
5 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2024 | −106.9 pp | GRFS |
| FY2023 | −183.0 pp | GRFS |
| FY2022 | −1143.7 pp | GRFS |
| FY2018 | −1242.8 pp | GRFS |
| FY2015 | −419.1 pp | GRFS |
GRFS has kept the higher net margin in every one of these 5 fiscal years.
5 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
ASND's net margin has been more volatile than GRFS's over the 5 comparable fiscal years — 478.9 percentage points of standard deviation against 5.0.
5 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
GRFS led in net margin in every one of the 5 comparable fiscal years — a structural lead, not a recent swing.
5 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
ASND's return on equity has been more volatile than GRFS's over the 8 comparable fiscal years — 20.4 percentage points of standard deviation against 5.3.
8 of 10 comparable fiscal years — a year missing data on either side is not counted.
Year by year
GRFS led in return on equity in every one of the 8 comparable fiscal years — a structural lead, not a recent swing.
8 of 10 comparable fiscal years — a year missing data on either side is not counted.